| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-02-01 | BMS (USA - NY) Pfizer (USA - NY) Portola Pharmaceuticals (USA - CA) | andexanet alfa and Eliquis® (apixaban) | reversion of the anticoagulant activity of Eliquis® | development - commercialisation | Cardiovascular diseases - Hematologic diseases | Development agreement |
| 2016-02-01 | Astellas Pharma (Japan) Clino Corporation (Japan) | adeno-associated virus-modified volvox channelrhodopsin-1 (AAV-mVChR1) | retinitis pigmentosa | license | Rare diseases - Genetic diseases - Ophtalmological diseases | Licensing agreement |
| 2016-01-30 | Novasep (France) Advanced Biotherapeutics Consulting (France) | collaboration |
Technology - Services | Collaboration agreement | ||
| 2016-01-29 | Allergan (Ireland), now Pfizer (USA - NY) AstraZeneca (UK) | ATM-AVI (aztreonam and avibactam) | infections caused by metallo ßlactamase MBL-producing Gram-negative pathogens | development commercialisation |
Infectious diseases | Development agreement |
| 2016-01-29 | Molmed (Italy) | restructuring |
Cancer - Oncology - Rare diseases | Restructuring | ||
| 2016-01-29 | Nicox (France) Ora (USA - MA) | AC-120 | morning eyelid swelling | licensing |
Ophtalmological diseases | Licensing agreement |
| 2016-01-28 | ALK Abello (Denmark) Abbott (USA - IL) | Acarizax®/Miticure™ | commercialisation distribution promotion |
Allergic diseases | Commercialisation agreement | |
| 2016-01-27 | Merck KGaA (Germany) | nomination |
Nomination | |||
| 2016-01-27 | Minoryx Therapeutics (Spain) | nomination |
Rare diseases | Nomination | ||
| 2016-01-27 | Ferring Pharmaceuticals (Switzerland) Karolinska Institutet (Sweden) | human microbiome translational research programme | collaboration R&D |
Gastrointestinal diseases - Digestive diseases | Collaboration agreement | |
| 2016-01-27 | Minoryx Therapeutics (Spain) | nomination |
Rare diseases - Genetic diseases | Nomination | ||
| 2016-01-26 | DBV Technologies (France) | nomination |
Allergic diseases - Immunological diseases | Nomination | ||
| 2016-01-26 | MorphoSys (Germany) Bayer (Germany) | anetumab ravtansine (BAY 94-9343) | mesothelioma | milestone | Cancer - Oncology | Milestone |
| 2016-01-26 | ImmunoGen (USA - MA) Bayer Healthcare (Germany) | anetumab ravtansine (BAY 94-9343) | R&D | Cancer - Oncology | Milestone | |
| 2016-01-25 | Affimed (Germany) Merck&Co (USA - NJ) | AFM13 (NK-cell TandAb generated against EGFRvIII) and Keytruda® (pembrolizumab) | patients with Hodgkin lymphoma whose disease has relapsed or is refractory to chemotherapy, including treatment with the marketed antibody-drug-conjugate Adcetris® (brentuximab vedotin) | clinical research |
Cancer - Oncology | Commercialisation agreement |
| 2016-01-25 | AstraZeneca (UK) GSK (UK) J&J (USA - NJ) Imperial College London (UK) the University of Cambridge (UK) University College London (UCL) (UK) | Apollo Therapeutics Fund | collaboration |
Collaboration agreement | ||
| 2016-01-25 | Onxeo (France) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2016-01-25 | Aduro Biotech (USA - CA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-01-25 | Acadia Pharmaceuticals (USA - CA) | nomination |
CNS diseases - Neurological diseases - Neurodegenerative diseases | Nomination | ||
| 2016-01-22 | Adaptimmune (UK) | nomination |
Cancer - Oncology - Autoimmune diseases | Nomination |
